EntryPoint Capital’s Autolus Therapeutics AUTL Stock Holding History

EntryPoint Capital’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-191,429	Closed	-$450K	–	686
2024 Q4	$450K	Buy	+191,429	New	+$647K	0.19%	148
2024 Q2	–	Sell	-21,540	Closed	-$137K	–	1399
2024 Q1	$137K	Buy	21,540 +11,456	+114%	+$71.5K	0.12%	261
2023 Q4	$64.9K	Buy	+10,084	New	+$38.5K	0.06%	602

Other funds holding AUTL

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EntryPoint Capital's AUTL Position: Q1 2025 in Review

EntryPoint Capital sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 191,429 shares — an estimated $450K sold.

EntryPoint Capital first reported a position in AUTL in Q4 2023 and held it in 3 quarters. The position peaked at $450K in Q4 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

EntryPoint Capital reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 191,429 Autolus Therapeutics shares in Q1 2025, an estimated $450K.
EntryPoint Capital first reported a position in Autolus Therapeutics in Q4 2023 and held it in 3 quarters.
EntryPoint Capital's Autolus Therapeutics position peaked at $450K in Q4 2024.
95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.